Inhibrx Biosciences INBX
NASDAQ INBX
$96.99 -0.94 (-0.96%)
At close: Oct 2, 2026 · 4:00 PM EDT

Inhibrx Biosciences (INBX) Gains from Sales and Divestitures (2023 - 2025)

Updated

Inhibrx Biosciences (INBX) recorded Gains from Sales and Divestitures of -$9,000 in Q4 2025.

Analysis

Inhibrx Biosciences (INBX) Gains from Sales and Divestitures (2023 - 2025) Analysis & Trends

For FY2025, Inhibrx Biosciences reported Gains from Sales and Divestitures of -$12,000.

  • Across earlier years, Gains from Sales and Divestitures came in at -$12,000 in FY2024 and -$3,000 in FY2023.
  • The Q4 2025 figure is the lowest quarterly Gains from Sales and Divestitures since Q3 2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Inhibrx Biosciences 1.43 Bn 1.43 Bn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 -9,000.00
Sep 30, 2025 -3,000.00
Sep 30, 2024 -12,000.00
Sep 30, 2023 -1,000.00
API Access

Inhibrx Biosciences Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=INBX&period=max&api_key=YOUR_API_KEY